Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection

Journal of Hepatology

Volumn 27, Issue 4, 1997, Pages 726-737

  Hervás Stubbs, Sandra ^a   Lasarte, Juan José ^a   Sarobe, Pablo ^a   Prieto, Jesús ^a   Cullen, John ^b   Roggendorf, Michael ^c   Borrás Cuesta, Francisco ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Antibodies; Hepatitis; Immune therapy; Peptides; T cell help; Vaccination; Woodchuck; Woodchuck hepatitis virus (WHV); Woodchuck hepatitis virus surface antigen (WHsAg)

Indexed keywords

HEPATITIS VACCINE;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; CHRONIC HEPATITIS; HELPER CELL; HEPATITIS VIRUS; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; VIRUS HEPATITIS; WOODCHUCK;

EID: 0343471379     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80090-6     Document Type: Article

References (40)

1. Ferrari C, Penna A, Bertoletti A, Valli A, Antoni AD, Giuberti T. Cellular immune response to hepatitis B virus (HBV) encoded antigens in acute and chronic HBV infection. J Immunol. 145:1990;3442-3449.
2. Chisari FV, Ferarri C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol. 13:1995;29-60.
3. Jung MC, Diepolder HM, Spengler U, Wierenga EA, Zachoval R, Hoffmann RM, et al. Activation of a heterogeneous Hepatitis B (HB) score and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J Virol. 69:1995;3358-8.
4. Diestag JL, Stevens CE, Bhan AK, Szmuness W. Hepatitis B vaccine administered to chronic carriers of hepatitis B surface antigen. Ann Int Med. 96:1982;575-579.
5. Wen Y-M, Wu X-H, Hu D-C, Zhang Q-P, Guo S-Q. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet. 345:1995;1575-1576.
6. Pol S, Driss F, Carnot F, Michel M-L, Berthelot P, Brechot C. Efficacité d'une immunothérapie par vaccination contre le virus de l'hépatite B sur la multiplication virale. C R Acad Sci. 316:1993;688-691.
7. Golvano JJ, Lasarte JJ, Sarobe P, Gullón A, Prieto J, Borrás-Cuesta F. Polarity of immunogens. Implications for vaccine design. Eur J Immunol. 20:1990;2363-2366.
8. Sarobe P, Lasarte JJ, Golvano JJ, Gullón A, Civeira MP, Prieto J, et al. Induction of antibodies against a peptide hapten does not require covalent linkage between the hapten and a class II presentable peptide. Eur J Immunol. 21:1991;1555-1558.
9. Hervás-Stubbs S, Berasain C, Golvano JJ, Lasarte JJ, Prieto I, Sarobe P, et al. Overcoming class II-linked non-responsiveness to hepatitis B vaccine. Vaccine. 12:1994;867-871.
10. Lasarte JJ, Sarobe P, Gullón A, Prieto J, Borrás-Cuesta F. Induction of cytotoxic T lymphocytes in mice against the principal neutralizing domain of HIV-1 by immunization with an engineered T-cytotoxic-T-helper synthetic peptide construct. Cell Immunol. 141:1992;211-218.
11. Lasarte JJ, Sarobe P, Prieto J, Borrás-Cuesta F. In vivo cytotoxic T-lymphocyte induction may take place via CD8+ T helper lymphocytes. Res Immunol. 146:1995;35-44.
12. Tenant BC, Gerin JL. The woodchuck model of hepatitis B virus infection. Arias IM, Boyer L, Fausto N, Jakoby WB, Schachter DA, Shafritz DA. 3rd ed. The Liver, Biology and Pathology. 1994;1455-1466 Raven Press Ltd, New York.
13. Roggendorf M, Tolle TK. The woodchuck: an animal model for hepatitis B virus infection in man. Intervirology. 38:1995;100-112.
14. Galibert F, Chen TN, Mandart E. Nucleotide sequence of a cloned Woodchuck hepatitis virus genome: comparison with the hepatitis B virus sequence. J Virol. 41:1982;51-65.
15. Summers J, Smolec JM, Snyder R. A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks. Proc Natl Acad Sci USA. 75:1978;4533-4537.
16. Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature. 317:1985;489-495.
17. Merrifield RB. Solid-phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 85:1963;2149-2154.
18. Atherton E, Logan JC, Sheppard RC. Peptide synthesis. II. Procedures for solid phase synthesis using N-fluorenil methoxicarbonyl amino acids on polyamide supports. Synthesis of substance P and of acyl carrier protein 65-74 decapeptide. J Chem Soc Perkin Trans. 1:1989;538-546.
19. Borrás-Cuesta F, Golvano JJ, Sarobe P, Lasarte JJ, Prieto I, Szabo A, et al. Insights on the amino acid chain interaction of a synthetic T-cell determinant. Biologicals. 19:1991;187-190.
20. Kaiser E, Colescott RL, Bossinger CD, Cook PI. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal Biochem. 34:1970;595-598.
21. Gerin JL, Faust RM, Holland PV. Biophysical characterization of the adr subtype of hepatitis B antigen and preparation of anti-r sera in rabbits. J Immunol. 115:1975;100-105.
22. Lai MZ, Ross DT, Guillet JG, Briner TJ, Gefter M, Smith JA. T lymphocyte response to bacteriophage lambda repressor cl protein. Recognition of the same peptide presented by Ia molecules of different haplotypes. J Immunol. 139:1987;3973-3980.
23. Persijn JP, van der Slik W. A new method for the determination of gamma glutamyltransferase in serum. J Clin Chem Clin Biochem. 14:1976;421-427.
24. Jendrassik L, Grof P. Photometric determination of bilirubin in urine. Biochem Z. 296:1938;71-79.
25. Maniatis T, Fritsch EF, Sambrook J. 1st ed. Molecular Cloning: a Laboratory Manual. 1982;Cold Spring Harbor, New York.
26. Bronstein I, Voyta JC, Thorpe GH, Kricka LJ. Chemiluminescent assay of alkaline phosphatase applied in an ultrasensitive enzyme immunoassay of thyrotropin. Clin Chem. 35:1989;1441-1446.
27. Menzo S, Bagnarelli P, Giacca M, Manzin A, Varaldo PE, Clementi M. Absolute quantitation of viremia in human immunodeficiency virus infection by competitive reverse transcription and polymerase chain reaction. J Clin Microbiol. 30:1992;1752-1757.
28. Cease KB, Berkower I, York-Jolley J, Berzofsky JA. T cell clones specific for an amphipathic α-helical region of sperm whale myoglobin show differing fine specificities for synthetic peptides. J Exp Med. 164:1986;1779-1784.
29. Brett S, Cease KB, Berzofsky JA. Influences of antigen processing on the expression of the T cell repertoire: evidence for MHC-specific hindering structures on the products of processing. J Exp Med. 168:1988;357-373.
30. Milich DR, Hughes JL, McLachlan A, Langley KE, Thornton GB, Jones JE. Importance of subtype in the immune response to the pre-S(2) region of the hepatitis B surface antigen. I. T cell fine specificity. J Immunol. 144:1990;3535-3543.
31. Korba BE, Cote PJ, Shapiro M, Purcell RH, Gerin JL. In vitro production of infectious woodchuck hepatitis virus by lipopolysaccharide-stimulated peripheral blood lymphocytes. J Infect Dis. 160:1989;572-576.
32. Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM. Reciprocal expression of interferon γ or interleukin 4 during the resolution or progression of murine leishmaniasis. J Exp Med. 169:1989;59-72.
33. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med. 177:1993;1505-1509.
34. Milich DR, Peterson DL, Schödel F, Jones JE, Hughes JI. Preferential recognition of hepatitis B nucleocapsid antigens by Th1 or Th2 cells is epitope and major histocompatibility complex dependent. J Virol. 69:1995;2776-2785.
35. Pfeiffer C, Stein J, Southwood S, Ketelaar H, Sette A, Bottomly K. Altered peptide ligands can control CD4T lymphocyte differentiation in vivo. J Exp Med. 181:1995;1569-1574.
36. Hart MK, Weinhold KJ, Scearce RM, Washburn EM, Clark CA, Palker TJ, et al. Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides. Proc Natl Acad Sci USA. 88:1991;9448-9452.
37. Shirai M, Pendleton CD, Ahlers J, Takeshita T, Newman M, Berzofsky JA. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. J Immunol. 152:1994;549-556.
38. Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. J Clin Invest. 95:1995;341-349.
39. Ilan Y, Nagler A, Adler R, Tur-Kaspa R, Slavin S, Shouval D. Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology. 104:1993;1818-1821.
40. Caselitz M, Link H, Hein R, Tischler HJ, Mascheck HJ, Böker K, et al. Fatal hepatitis B reactivation after bone marrow transplantation (Abstract). J Hepatol. 23:1995;108. P/C1/86.